Value
3.3/10data confidence 67%| Component | Sub-score |
|---|---|
| P/S | 0.0 |
| Fwd P/E | 1.0 |
| PEG | 6.4 |
| Analyst target | 9.0 |
- ▸Forward P/E: 131.5x
- ▸PEG: 1.15
BBIO · Why this verdict
Why BridgeBio Pharma (BBIO) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.4/10
ConfidenceMEDIUM
MacroNEUTRAL
TrendMatrix Research · core thesis
Engine thesis — one sentence
A company delivering 67% year-over-year revenue growth with strong price momentum, rising on-balance volume, and a 4.4-to-1 favorable risk/reward offers a compelling long-term opportunity, but 3 of the 4 most recent quarters missed earnings estimates, a forward price-to-earnings of 137x demands flawless execution, and revenue concentration in two lead products creates meaningful fragility that warrants careful position sizing.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Revenue is concentrated in two commercial products—Attruby and Beyonttra—meaning any setback in patient uptake, pricing, or competitive entry for either product could materially impair the growth trajectory that justifies the current valuation. Bear case | Products other than the two lead therapies contribute more than 20% of total revenues within 12 months, reducing single-product dependency. | →Stable |
| CounterDeep focus on a small number of breakthrough treatments can reflect high commercial quality and pricing power in a specialty or rare-disease niche, where product concentration often accompanies superior margins rather than fragility. | ||
Revenue grew 67% year-over-year, placing the company at the top of its peer group for growth performance and supporting the bull case for a commercial ramp in its product portfolio that is materializing faster than peers. Growth breakdown | Revenue continues growing at 40% or more year-over-year for at least 2 of the next 4 quarters, sustaining the top-quartile growth trajectory. | →Stable |
| CounterRapid top-line expansion is concentrated in two commercial products, meaning any slowdown in patient uptake, pricing pressure, or label limitation could sharply reduce the growth rate without warning. | ||
The stock trades above its 200-day moving average with rising on-balance volume and a bullish MACD configuration, signaling sustained institutional accumulation and a positive price trend that has cleared the momentum gate. Momentum breakdown | Price sustains above the 200-day moving average for the next 6 months while on-balance volume continues its rising trend, confirming the accumulation thesis. | →Stable |
| CounterRSI at mid-range and Bollinger positioning in the neutral zone suggest the trend is intact but not accelerating; any earnings miss could push the price below the 200-day moving average and reset the momentum setup. | ||
At a forward price-to-earnings of 137x, the stock screens expensive on nearly every valuation metric, requiring flawless near-term execution to avoid a multiple compression that could overwhelm even strong revenue growth. Valuation breakdown | Forward P/E compresses below 80x from the current 137x as earnings ramp accelerates and the market gains confidence in the path to profitability. | →Stable |
| CounterA PEG of 1.21 suggests the 137x forward multiple may be less stretched than the raw figure implies when the growth rate is properly accounted for; commercial-ramp phase valuations often appear extreme before profitability inflects. | ||
The company missed analyst earnings estimates in 3 of the 4 most recent quarters, including 2 consecutive misses of -36% and -51% in the most recently reported periods, raising questions about management's ability to set realistic near-term guidance. Earnings | EPS surprise rate rises above 10% for 2 consecutive quarters from the current trailing average of -34%, demonstrating improved execution discipline relative to guidance. | →Stable |
| CounterThe one beat in the series showed a 7.7% positive surprise, and the company is in a high-investment ramp phase where quarterly volatility around loss estimates is common and may reflect investment timing rather than structural under-delivery. | ||
Revenue is concentrated in two commercial products—Attruby and Beyonttra—meaning any setback in patient uptake, pricing, or competitive entry for either product could materially impair the growth trajectory that justifies the current valuation.
→StableBear case
- Expectation
- Products other than the two lead therapies contribute more than 20% of total revenues within 12 months, reducing single-product dependency.
CounterDeep focus on a small number of breakthrough treatments can reflect high commercial quality and pricing power in a specialty or rare-disease niche, where product concentration often accompanies superior margins rather than fragility.
Revenue grew 67% year-over-year, placing the company at the top of its peer group for growth performance and supporting the bull case for a commercial ramp in its product portfolio that is materializing faster than peers.
→StableGrowth breakdown
- Expectation
- Revenue continues growing at 40% or more year-over-year for at least 2 of the next 4 quarters, sustaining the top-quartile growth trajectory.
CounterRapid top-line expansion is concentrated in two commercial products, meaning any slowdown in patient uptake, pricing pressure, or label limitation could sharply reduce the growth rate without warning.
The stock trades above its 200-day moving average with rising on-balance volume and a bullish MACD configuration, signaling sustained institutional accumulation and a positive price trend that has cleared the momentum gate.
→StableMomentum breakdown
- Expectation
- Price sustains above the 200-day moving average for the next 6 months while on-balance volume continues its rising trend, confirming the accumulation thesis.
CounterRSI at mid-range and Bollinger positioning in the neutral zone suggest the trend is intact but not accelerating; any earnings miss could push the price below the 200-day moving average and reset the momentum setup.
At a forward price-to-earnings of 137x, the stock screens expensive on nearly every valuation metric, requiring flawless near-term execution to avoid a multiple compression that could overwhelm even strong revenue growth.
→StableValuation breakdown
- Expectation
- Forward P/E compresses below 80x from the current 137x as earnings ramp accelerates and the market gains confidence in the path to profitability.
CounterA PEG of 1.21 suggests the 137x forward multiple may be less stretched than the raw figure implies when the growth rate is properly accounted for; commercial-ramp phase valuations often appear extreme before profitability inflects.
The company missed analyst earnings estimates in 3 of the 4 most recent quarters, including 2 consecutive misses of -36% and -51% in the most recently reported periods, raising questions about management's ability to set realistic near-term guidance.
→StableEarnings
- Expectation
- EPS surprise rate rises above 10% for 2 consecutive quarters from the current trailing average of -34%, demonstrating improved execution discipline relative to guidance.
CounterThe one beat in the series showed a 7.7% positive surprise, and the company is in a high-investment ramp phase where quarterly volatility around loss estimates is common and may reflect investment timing rather than structural under-delivery.
Per-dimension breakdown
Quality
4.0/10data confidence 100%| Component | Sub-score |
|---|---|
| ROA | 0.0 |
| Gross margin | 10.0 |
| Op margin | 0.0 |
| Current ratio | 5.6 |
| FCF quality | 0.0 |
| Moat | 7.0 |
| Rule of 40 | 3.0 |
| Piotroski F | 6.7 |
- ▸Cash-burning: FCF -55% of revenue
- ▸Rule of 40: 12 (fail)
Growth
10.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Rev growth | 10.0 |
| EPS growth | 10.0 |
- ▸Strong growth: 67% YoY
Momentum
6.8/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 5.0 |
| MACD | 10.0 |
| OBV | 10.0 |
| MA position | 9.0 |
| Volume | 0.0 |
- ▸Volume accumulation (rising OBV)
- ▸Above 200-day MA
Sentiment
8.6/10data confidence 100%| Component | Sub-score |
|---|---|
| LLM sentiment | 7.5 |
| Analyst rating | 9.0 |
| Price target | 9.4 |
- ▸LLM news sentiment: +0.50 (n=1)
- ▸Analyst upside: 46%
Insider
3.4/10data confidence 75%| Component | Sub-score |
|---|---|
| materiality | 3.0 |
| insider conviction | 2.0 |
| holder change | 5.1 |
- ▸Notable insider selling — $20,289,869 (0.149% of mkt cap)
Peer rank
3.7/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 2.5 |
| quality rank | 0.0 |
| growth rank | 7.3 |
Technical
2.4/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 0.0 |
| support resistance | 0.6 |
| 52w position | 6.5 |
Risk (lower is worse)
5.5/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 3.0 |
| days to cover | 1.1 |
| volatility | 4.4 |
| put call | 10.0 |
| implied vol | 6.0 |
| max pain risk | 7.0 |
| beta | 7.2 |
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
3.0/10data confidence 100%| Component | Sub-score |
|---|---|
| erm | 5.0 |
| earnings history | 0.0 |
| earnings timing | 5.0 |
| surprise avg | 0.0 |
| news activity | 5.0 |
- ▸Earnings concerns: 1B/3M
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (7)
- MOMENTUM:6.8>=5.5
- ASYMMETRY:2.8>=1.5
- INSIDER:OK
- 8K:CLEAN
- EARNINGS_PROXIMITY:40d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (0)
none
Warning (0)
none
Reward-to-Risk
2.81
Upside
+31.0%
Downside
11.0%
Sizing output
AVOID
SetupBREAKOUT — Golden cross, above all MAs, RSI 63, MACD bullish
EdgeNO_EDGE — No clear edge identified
SuitabilityMODERATE — Balanced profile
Investment implication
The F-path SELL output reflects an overall score of 5.4 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Growth at 10.0) was not enough to lift the adjusted overall above the threshold. Current asymmetry R:R is 2.81 — supplementary context, not the trigger for this path.
The strongest dimensions are Growth at 10.0, Sentiment at 8.6, and Momentum at 6.8; the weakest are Technical at 2.4, Catalyst at 3.0, and Value at 3.3. The V9 engine cleared all gates, producing an asymmetric reward-to-risk of 2.81 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Revenue grew 67% year-over-year, placing the company at the top of its peer group for growth performance and supporting the bull case for a commercial ramp in its product portfolio that is materializing faster than peers.
Trip ifRevenue growth falls below 30% year-over-year for 2 consecutive quarters from the current 67% pace.
- P2The stock trades above its 200-day moving average with rising on-balance volume and a bullish MACD configuration, signaling sustained institutional accumulation and a positive price trend that has cleared the momentum gate.
Trip ifPrice falls more than 15% below the current $68.00 and stays under the 200-day moving average for more than 30 consecutive days.
- P3At a forward price-to-earnings of 137x, the stock screens expensive on nearly every valuation metric, requiring flawless near-term execution to avoid a multiple compression that could overwhelm even strong revenue growth.
Trip ifForward P/E fails to compress below 100x within 12 months despite continued revenue growth, indicating the market is unwilling to re-rate the multiple.
- P4The company missed analyst earnings estimates in 3 of the 4 most recent quarters, including 2 consecutive misses of -36% and -51% in the most recently reported periods, raising questions about management's ability to set realistic near-term guidance.
Trip ifEPS surprise rate rises above 10% for 2 consecutive quarters from the current trailing average of -34%.
- P5Revenue is concentrated in two commercial products—Attruby and Beyonttra—meaning any setback in patient uptake, pricing, or competitive entry for either product could materially impair the growth trajectory that justifies the current valuation.
Trip ifProducts other than the two lead therapies exceed 20% of total revenues in the next annual report disclosure, reducing single-product concentration.